医药导报
醫藥導報
의약도보
HERALD OF MEDICINE
2015年
7期
851-855
,共5页
刘泰%黄德庆%张元侃%李丹%黄树武%谭璐璐%刘永辉%李生%姚平%宋曦%何乾超
劉泰%黃德慶%張元侃%李丹%黃樹武%譚璐璐%劉永輝%李生%姚平%宋晞%何乾超
류태%황덕경%장원간%리단%황수무%담로로%류영휘%리생%요평%송희%하건초
疏血通脉胶囊%预处理,脑缺血%缺血-再灌注,脑%p38丝裂原激活蛋白激酶
疏血通脈膠囊%預處理,腦缺血%缺血-再灌註,腦%p38絲裂原激活蛋白激酶
소혈통맥효낭%예처리,뇌결혈%결혈-재관주,뇌%p38사렬원격활단백격매
目的:研究疏血通脉胶囊预处理对大脑中动脉闭塞再灌注大鼠脑保护作用及对脑内p38丝裂原激活蛋白激酶(p38MAPK)表达的影响。方法将96只雄性SD大鼠随机分为4组,每组24只,每组按照再灌注后3,6,24,72 h随机分为4个亚组,每个亚组6只。假手术组只分离动脉不插线。缺血-再灌注组建成大脑中动脉闭塞再灌注( MCAO)模型。预缺血组脑缺血预处理,24 h后建立MCAO模型;疏血通脉组先给予疏血通脉胶囊14 d,再制备MCAO模型。 Zea Longa法进行神经功能缺损评分,免疫印迹法检测p38MAPK、P-p38MAPK表达,Tunel 法检测神经元凋亡数量,观察p38MAPK、P-p38MAPK表达水平与神经元凋亡相关性。结果假手术组各时间点均未出现神经功能缺损,其余各组大鼠各时间点均出现不同程度神经功能缺损,并均于24 h达高峰。与缺血-再灌注组比较,预缺血组和疏血通脉组各时间点神经功能缺损情况较轻(P<0.05)。预缺血组与疏血通脉组各时间点神经功能缺损情况相当。假手术组不同时间点P-p38MAPK/p38MAPK比值未见明显变化;其他3组P-p38MAPK/p38MAPK比值增大,且随再灌注时间延长,该比值逐渐升高,24 h达到高峰。预缺血组和疏血通脉组从3 h起,P-p38MAPK/p38MAPK比值减小,并随再灌注时间延长逐渐下降,24 h最低,与缺血-再灌注组比较,均差异有统计学意义(P<0.05)。预缺血组与疏血通脉组不同时间点磷酸化水平相当。假手术组各时间点偶见极少量凋亡神经元,其他各组随再灌注时间延长,神经元凋亡数量逐渐增加,并于24 h达到高峰。预缺血组和疏血通脉组不同时间点神经元凋亡数量均较缺血-再灌注组少(P<0.05)。结论疏血通脉胶囊预处理可诱导大鼠脑缺血耐受,减少脑缺血-再灌注后神经元凋亡,改善神经功能,其机制可能与抑制p38MAPK磷酸化有关。
目的:研究疏血通脈膠囊預處理對大腦中動脈閉塞再灌註大鼠腦保護作用及對腦內p38絲裂原激活蛋白激酶(p38MAPK)錶達的影響。方法將96隻雄性SD大鼠隨機分為4組,每組24隻,每組按照再灌註後3,6,24,72 h隨機分為4箇亞組,每箇亞組6隻。假手術組隻分離動脈不插線。缺血-再灌註組建成大腦中動脈閉塞再灌註( MCAO)模型。預缺血組腦缺血預處理,24 h後建立MCAO模型;疏血通脈組先給予疏血通脈膠囊14 d,再製備MCAO模型。 Zea Longa法進行神經功能缺損評分,免疫印跡法檢測p38MAPK、P-p38MAPK錶達,Tunel 法檢測神經元凋亡數量,觀察p38MAPK、P-p38MAPK錶達水平與神經元凋亡相關性。結果假手術組各時間點均未齣現神經功能缺損,其餘各組大鼠各時間點均齣現不同程度神經功能缺損,併均于24 h達高峰。與缺血-再灌註組比較,預缺血組和疏血通脈組各時間點神經功能缺損情況較輕(P<0.05)。預缺血組與疏血通脈組各時間點神經功能缺損情況相噹。假手術組不同時間點P-p38MAPK/p38MAPK比值未見明顯變化;其他3組P-p38MAPK/p38MAPK比值增大,且隨再灌註時間延長,該比值逐漸升高,24 h達到高峰。預缺血組和疏血通脈組從3 h起,P-p38MAPK/p38MAPK比值減小,併隨再灌註時間延長逐漸下降,24 h最低,與缺血-再灌註組比較,均差異有統計學意義(P<0.05)。預缺血組與疏血通脈組不同時間點燐痠化水平相噹。假手術組各時間點偶見極少量凋亡神經元,其他各組隨再灌註時間延長,神經元凋亡數量逐漸增加,併于24 h達到高峰。預缺血組和疏血通脈組不同時間點神經元凋亡數量均較缺血-再灌註組少(P<0.05)。結論疏血通脈膠囊預處理可誘導大鼠腦缺血耐受,減少腦缺血-再灌註後神經元凋亡,改善神經功能,其機製可能與抑製p38MAPK燐痠化有關。
목적:연구소혈통맥효낭예처리대대뇌중동맥폐새재관주대서뇌보호작용급대뇌내p38사렬원격활단백격매(p38MAPK)표체적영향。방법장96지웅성SD대서수궤분위4조,매조24지,매조안조재관주후3,6,24,72 h수궤분위4개아조,매개아조6지。가수술조지분리동맥불삽선。결혈-재관주조건성대뇌중동맥폐새재관주( MCAO)모형。예결혈조뇌결혈예처리,24 h후건립MCAO모형;소혈통맥조선급여소혈통맥효낭14 d,재제비MCAO모형。 Zea Longa법진행신경공능결손평분,면역인적법검측p38MAPK、P-p38MAPK표체,Tunel 법검측신경원조망수량,관찰p38MAPK、P-p38MAPK표체수평여신경원조망상관성。결과가수술조각시간점균미출현신경공능결손,기여각조대서각시간점균출현불동정도신경공능결손,병균우24 h체고봉。여결혈-재관주조비교,예결혈조화소혈통맥조각시간점신경공능결손정황교경(P<0.05)。예결혈조여소혈통맥조각시간점신경공능결손정황상당。가수술조불동시간점P-p38MAPK/p38MAPK비치미견명현변화;기타3조P-p38MAPK/p38MAPK비치증대,차수재관주시간연장,해비치축점승고,24 h체도고봉。예결혈조화소혈통맥조종3 h기,P-p38MAPK/p38MAPK비치감소,병수재관주시간연장축점하강,24 h최저,여결혈-재관주조비교,균차이유통계학의의(P<0.05)。예결혈조여소혈통맥조불동시간점린산화수평상당。가수술조각시간점우견겁소량조망신경원,기타각조수재관주시간연장,신경원조망수량축점증가,병우24 h체도고봉。예결혈조화소혈통맥조불동시간점신경원조망수량균교결혈-재관주조소(P<0.05)。결론소혈통맥효낭예처리가유도대서뇌결혈내수,감소뇌결혈-재관주후신경원조망,개선신경공능,기궤제가능여억제p38MAPK린산화유관。
Objective To explore the neuroprotection of Shuxuetongmai capsule pretreatment, and the effect on the expression of p38 mitogen-activated protein kinase (p38MAPK) in rats with middle cerebral artery occlusion. Methods Ninety-six male SD rats were divided randomly into sham-operated group,ischemia/reperfusion group (I/R),ischemia preconditioning group (IP),and Shuxuetongmai group(n=24). Each group was further randomly divided into 4 subgroups by 3 h, 6 h, 24 h and 72 h after reperfusion, 6 rats in each subgroup. Sham-operated group was only performed artery separation . The middle cerebral artery occlusion (MCAO) model was set up in I/R rats by Longa method. The IP rats were performed for three minutes on the bilateral carotid artery ligation, and formed MCAO model 24 hours later. The rats in the Shuxuetongmai group were pretreated with Shuxuetongmai capsules for 14 days on gavage before the establishment of MCAO model. The neurological deficits were graded in rats by Zea Longa method. Western Blot was used to determine the protein expression of p38MAPK and P-p38MAPK. Tunel method was applied to detect the apoptosis of neurons and the relationship between expression of p38MAPK, P-p38MAPK and apoptosis of neuron. Results No neurological dysfunction appeared in the sham-operated group at each time points, but not for the other groups, which reached the peak at 24 h. Compared with the I/R group, IP group and Shuxuetongmai group presented the mild neurologic function deficiency at different time points in rats (P<0. 05), and no significant differences occurred between ischemia preconditioning group and Shuxuetongmai group (P>0.05). The obvious variation of the value of P-p38MAPK/p38MAPK wasn't detected in sham-operated group at different time points, while obviously presented in I/R group, and the ratios of P-p38MAPK/p38MAPK were increased gradually followed with reperfusion, approaching to the highest level at 24 h. Compared with the I/R group, the P-p38MAPK/p38MAPK declined from 3 h and to the lowest level at 24 h of reperfusion, in both IP and Shuxuetongmai groups(P<0. 05), and with similar phosphorylation. At different time points,very few neurons apoptosis were detected in sham-operated groups, but which increased gradually after reperfusion in other groups, and reached to the peak at 24 h. The neurons apoptosis in both IP group and Shuxuetongmai group were less than that in IR group ( P<0. 05 ) at different time points, and it showed no significant differences on neurons apoptosis between ischemia/preconditioning group and Shuxuetongmai group in rats (P>0. 05). Conclusion Shuxuetongmai capsule pretreatment can induce brain ischemic tolerance, attenuate the apoptosis of neurons in cerebral ischemia reperfusion, and improve neurologic function. The mechanism may be related to the inhibition of p38MAPK phosphorylation.